Systemic cellular viroimmunotherapy for canine high-grade gliomas
J Immunother Cancer. 2022 Dec;10(12):e005669. doi: 10.1136/jitc-2022-005669.ABSTRACTBACKGROUND:…
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer J. 2023 Jan 5;13(1):8. doi: 10.1038/s41408-022-00778-3.ABSTRACTThe…
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer
J Immunother Cancer. 2022 Dec;10(12):e005443. doi: 10.1136/jitc-2022-005443.ABSTRACTBACKGROUND:…
Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas
Transplant Cell Ther. 2023 Mar;29(3):184.e1-184.e9. doi: 10.1016/j.jtct.2022.11.028.…
An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Transplant Cell Ther. 2023 Apr;29(4):279.e1-279.e10. doi: 10.1016/j.jtct.2022.12.013.…
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
Cancers (Basel). 2022 Dec 11;14(24):6101. doi: 10.3390/cancers14246101.ABSTRACTEpithelial-to-mesenchymal…
Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
Cancers (Basel). 2022 Dec 16;14(24):6214. doi: 10.3390/cancers14246214.ABSTRACTEpithelial-to-mesenchymal…
Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15-26]
Eur Urol. 2023 Mar;83(3):e87. doi: 10.1016/j.eururo.2022.11.025.…
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913.…
Local Resection in Choroidal Melanoma: A Review
J Clin Med. 2022 Dec 1;11(23):7156. doi: 10.3390/jcm11237156.ABSTRACTSurgical…
Circulating levels of MOTS-c in patients with breast cancer treated with metformin
Aging (Albany NY). 2022 Dec 6;15(4):892-897. doi: 10.18632/aging.204423.…
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies
Int J Hematol. 2023 Mar;117(3):388-397. doi: 10.1007/s12185-022-03488-5.…
